表紙
市場調查報告書

產前·新生兒遺傳基因檢查的全球市場:產業分析·地區的展望·潛在性用途 ·價格趨勢·市場佔有率·成長預測

Prenatal and New-born Genetic Testing Market Size By Technology, By Disease, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024

出版商 Global Market Insights Inc. 商品編碼 648630
出版日期 內容資訊 英文 140 Pages
商品交期: 2-3個工作天內
價格
Back to Top
產前·新生兒遺傳基因檢查的全球市場:產業分析·地區的展望·潛在性用途 ·價格趨勢·市場佔有率·成長預測 Prenatal and New-born Genetic Testing Market Size By Technology, By Disease, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024
出版日期: 2018年05月28日內容資訊: 英文 140 Pages
簡介

產前·新生兒遺傳基因檢查市場預測到2024年將超越70億美元

本報告提供全球產前·新生兒遺傳基因檢查的市場調查,彙整市場定義和概要,產業的背景,市場成長的各種影響因素分析,法律制度,各技術·疾病·最終用途·地區市場規模的變化與預測,主要企業簡介等資訊。

第1章 調查手法

第2章 摘要整理

第3章 產前·新生兒遺傳基因檢查:產業分析

  • 產業區分
  • 產業環境
  • 對產業的影響因素
    • 成長推進因素
    • 課題
  • 成長的潛在性分析
  • 法律制度
  • 波特的五力分析
  • 競爭環境
  • PESTEL分析

第4章 產前·新生兒遺傳基因檢查市場:各技術

  • 全球產前·新生兒遺傳基因檢查市場佔有率:各技術
  • 篩檢
    • CVS (絨毛採樣)
    • 母體血清篩檢
    • 羊水穿刺
    • 非侵襲產前檢查
  • 診斷
    • mmPCR
    • 分光光度計
    • FISH法
    • 化驗

第5章 產前·新生兒遺傳基因檢查市場:各疾病

  • 全球產前·新生兒遺傳基因檢查市場佔有率:各疾病
  • 唐氏症
  • 苯酮尿症
  • 囊狀纖維化症
  • 鐮狀細胞貧血症
  • 其他

第6章 產前·新生兒遺傳基因檢查市場:各最終用途

  • 全球產前·新生兒遺傳基因檢查市場佔有率:各最終用途
  • 醫院
  • 婦產科診所·專門診療所
  • 診斷中心

第7章 產前·新生兒遺傳基因檢查市場:各地區

  • 全球產前·新生兒遺傳基因檢查市場佔有率:各地區
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東·非洲
    • 沙烏地阿拉伯
    • 南非

第8章 企業簡介

  • Abbott
  • Agilent
  • AutoGenomics
  • Ariosa Diagnostics
  • Baebies
  • Berry Genomics Co. Ltd
  • BGI
  • Biocartis Group NV
  • Bio-Rad Laboratories, Inc.
  • Illumina Inc.
  • Laboratory Corporation of America
  • Masimo Corporation
  • Natera Inc.
  • Perkinelmer, Inc.
  • Progenity, Inc.
  • Qiagen
  • Sequenom Inc.
  • Trivitron Healthcare Private Limited
目錄
Product Code: 1906

Title:
Prenatal and New-born Genetic Testing Market Size By Technology (Screening {Chorionic Villus Sampling, Maternal Serum Screening, Amniocentesis, Non-invasive prenatal testing}, Diagnostic {mmPCR, Spectrophotometer, FISH, Assays), By Disease (Downs Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anaemia), By End-use (Hospitals, Maternity & Specialty Clinics, Diagnostic Centres), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Italy, France, Spain, China, India, Japan, Australia, Brazil, Mexico, Argentina, Saudi Arabia, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024.

Prenatal and New-born Genetic Testing Market will exceed USD 7 billion by 2024; as per a new research report.

Technological advancement and several benefits associated with infant genetic testing will be major driver of the prenatal and new-born genetic testing market. Introduction of prenatal testing has led to substantial amount of increase in adoption rate of new testing technologies such as non-invasive prenatal testing (NIPT) for detection of sub chromosomal abnormalities, single-gene disorders and aneuploidy in North America region. Inclination towards minimally invasive infant genetic testing along with demand for early detection of birth defects will one of the major reason for market growth.

Rising number of consanguineous relations in the developing countries of Asia and Middle East will foster growth opportunities for prenatal and newborn genetic testing market. The consanguineous relations are responsible for births of infants with defects and chromosomal abnormalities. Consequent, the increase in cases of live births diagnosed with birth defects will directly impact the growth of prenatal and new-born genetic testing market.

Increasing prevalence of birth defects among the European population is one of the major reason for rising infant mortality. The necessary government initiatives in order to conduct prenatal and new-born genetic tests to diagnose the birth defects will increase the number of infant screening programs giving rise to market growth opportunities.

However, lack of infrastructure and skilled labor in the low and middle income countries will impede the parental and newborn genetic testing market growth. Moreover, ethical issues associated with prenatal and newborn testing coupled with incidences of false test results will further hamper industry growth.

Screening technology holds majority of market share in the year 2017 owing to increasing number of screening procedures of pregnant women while delivery. The rise in awareness among the families regarding genetic birth defects and early detection of genetic disorder will augment the segment growth in the near future.

Downs Syndrome recorded largest market share in the prenatal and newborn genetic testing market due to increasing in number of births diagnosed with Downs syndrome. The rise in incidences of women getting married at later stage of life is leading to increasing births with Downs Syndrome. These factors will further support the segment growth over the forecast timeframe.

Hospitals hold the majority of market share owing to increasing number of births in hospitals. Hospitals are aided by the government and provide the facilities require for the newborn screening. The increase in number of screening programs in hospitals provides significant scope for the market growth.

U.S. dominated the market in 2017 owing to ongoing technological advancements along with favorable reimbursement policies. The U.S. region had 99% of newborn screening rate and high awareness about prenatal and new-born genetic testing will be responsible for the market growth in U.S. Presence of technologically advanced and equipped manufacturing companies along with government initiatives supporting screening activities that will impel market growth.

Some of the major market players competing in global prenatal and newborn genetic testing market are Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health. The competitors are using launch of novel products with technological advancements, acquisitions and mergers as the key strategies to foresee a lucrative growth in prenatal and newborn genetic testing market. For example, In March 2018, Natera declared a partnership with QIAGEN to develop cell-free DNA assays for QIAGEN's GeneReader NGS System. These DNA assays will be developed and designed for tests, including prenatal screening, for laboratories and hospitals globally.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
    • 1.1.1. Initial data exploration
    • 1.1.2. Statistical model and forecast
    • 1.1.3. Industry insights and validation
    • 1.1.4. Market definition and forecast parameters
  • 1.2. Data sources
    • 1.2.1. Secondary
    • 1.2.2. Primary

Chapter 2. Executive Summary

  • 2.1. Precision medicine industry 360 degree synopsis, 2013 - 2024
    • 2.1.1. Business trends
    • 2.1.2. Technology trends
    • 2.1.3. Disease trends
    • 2.1.4. End-use trends
    • 2.1.5. Regional trends

Chapter 3. Prenatal and New-born Genetic Testing Market Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2013 - 2024
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
    • 3.3.1.1. Technological advancements and increasing benefits in the field of prenatal testing and newborn genetic screening in North America
    • 3.3.1.2. Increasing prevalence of genetic disorders and chromosomal abnormalities in Europe
    • 3.3.1.3. Rising consanguineous relations in countries of APAC and Middle east and Africa
    • 3.3.1.4. Government initiatives and support for prenatal testing and newborn genetic screening in Asia-Pacific
    • 3.3.1.5. Rise in adoption of Noninvasive Prenatal Testing in Latin America
    • 3.3.2. Industry pitfalls & challenges
    • 3.3.2.1. Increasing false results for prenatal tests in Europe
    • 3.3.2.2. Lack of advanced infrastructure and skilled labor in developing region of Latin America and Asia-Pacific
    • 3.3.2.3. Ethical issues to prenatal testing and newborn genetic screening in Asia-Pacific and Middle East and Africa
  • 3.4. Growth potential analysis
    • 3.4.1. By technology
    • 3.4.2. By disease
    • 3.4.3. By end-use
  • 3.5. Regulatory landscape
    • 3.5.1. U.S
    • 3.5.2. Europe
  • 3.6. Porter's analysis
  • 3.7. Competitive landscape, 2017
    • 3.7.1. Business overview
    • 3.7.2. Revenue analysis
    • 3.7.3. Product landscape
    • 3.7.4. Strategy dashboard
  • 3.8. PESTEL analysis

Chapter 4. Prenatal and New-born Genetic Testing Market, By Technology

  • 4.1. Global Prenatal & Newborn Genetic Testing Market share, by technology, 2017 & 2024
  • 4.2. Screening
    • 4.2.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.2.2. Chorionic Villus Sampling
    • 4.2.2.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.2.3. Maternal Serum Screening
    • 4.2.3.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.2.4. Amniocentesis
    • 4.2.4.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.2.5. Non-invasive prenatal testing
    • 4.2.5.1. Market estimates and forecast, by region, 2013 - 2024
  • 4.3. Diagnostic
    • 4.3.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.3.2. mmPCR
    • 4.3.2.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.3.3. Spectrophotometer
    • 4.3.3.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.3.4. FISH
    • 4.3.4.1. Market estimates and forecast, by region, 2013 - 2024
    • 4.3.5. ASSAYS
    • 4.3.5.1. Market estimates and forecast, by region, 2013 - 2024

Chapter 5. Prenatal and New-born Genetic Testing Market, By Disease

  • 5.1. Global Prenatal & Newborn Genetic Testing Market share, by disease, 2017 & 2024
  • 5.2. Downs Syndrome
    • 5.2.1. Market estimates and forecast, by region, 2013 - 2024
  • 5.3. Phenylketonuria
    • 5.3.1. Market estimates and forecast, by region, 2013 - 2024
  • 5.4. Cystic Fibrosis
    • 5.4.1. Market estimates and forecast, by region, 2013 - 2024
  • 5.5. Sickle Cell Anemia
    • 5.5.1. Market estimates and forecast, by region, 2013 - 2024
  • 5.6. Others
    • 5.6.1. Market estimates and forecast, by region, 2013 - 2024

Chapter 6. Prenatal and New-born Genetic Testing Market, By End-use

  • 6.1. Global Prenatal & Newborn Genetic Testing Market share, by end-use, 2017 & 2024
  • 6.2. Hospitals
    • 6.2.1. Market estimates and forecast, by region, 2013 - 2024
  • 6.3. Maternity and Specialty Clinics
    • 6.3.1. Market estimates and forecast, by region, 2013 - 2024
  • 6.4. Diagnostic Centers
    • 6.4.1. Market estimates and forecast, by region, 2013 - 2024

Chapter 7. Prenatal and New-born Genetic Testing Market, By Region

  • 7.1. Prenatal & Newborn Genetic Testing Market share, by region, 2017 & 2024
  • 7.2. North America
    • 7.2.1. Market estimates and forecast, by country, 2013 - 2024
    • 7.2.2. Market estimates and forecast, by technology, 2013 - 2024
    • 7.2.2.1. Market estimates and forecast, by screening, 2013 - 2024
    • 7.2.2.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.2.3. Market estimates and forecast, by disease, 2013 - 2024
    • 7.2.4. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.2.5. U.S.
    • 7.2.5.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.2.5.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.2.5.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.2.5.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.2.5.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.2.6. Canada
    • 7.2.6.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.2.6.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.2.6.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.2.6.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.2.6.3. Market estimates and forecast, by end-use, 2013 - 2024
  • 7.3. Europe
    • 7.3.1. Market estimates and forecast, by country, 2013 - 2024
    • 7.3.2. Market estimates and forecast, by technology, 2013 - 2024
    • 7.3.2.1. Market estimates and forecast, by screening, 2013 - 2024
    • 7.3.2.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.3.3. Market estimates and forecast, by disease, 2013 - 2024
    • 7.3.4. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.3.5. Germany
    • 7.3.5.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.3.5.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.3.5.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.3.5.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.3.5.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.3.6. UK
    • 7.3.6.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.3.6.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.3.6.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.3.6.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.3.6.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.3.7. France
    • 7.3.7.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.3.7.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.3.7.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.3.7.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.3.7.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.3.8. Italy
    • 7.3.8.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.3.8.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.3.8.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.3.8.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.3.8.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.3.9. Spain
    • 7.3.9.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.3.9.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.3.9.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.3.9.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.3.9.3. Market estimates and forecast, by end-use, 2013 - 2024
  • 7.4. Asia Pacific
    • 7.4.1. Market estimates and forecast, by country, 2013 - 2024
    • 7.4.2. Market estimates and forecast, by technology, 2013 - 2024
    • 7.4.2.1. Market estimates and forecast, by screening, 2013 - 2024
    • 7.4.2.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.4.3. Market estimates and forecast, by disease, 2013 - 2024
    • 7.4.4. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.4.5. Japan
    • 7.4.5.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.4.5.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.4.5.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.4.5.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.4.5.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.4.6. China
    • 7.4.6.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.4.6.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.4.6.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.4.6.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.4.6.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.4.7. India
    • 7.4.7.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.4.7.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.4.7.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.4.7.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.4.7.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.4.8. Australia
    • 7.4.8.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.4.8.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.4.8.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.4.8.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.4.8.3. Market estimates and forecast, by end-use, 2013 - 2024
  • 7.5. Latin America
    • 7.5.1. Market estimates and forecast, by country, 2013 - 2024
    • 7.5.2. Market estimates and forecast, by technology, 2013 - 2024
    • 7.5.2.1. Market estimates and forecast, by screening, 2013 - 2024
    • 7.5.2.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.5.3. Market estimates and forecast, by disease, 2013 - 2024
    • 7.5.4. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.5.5. Brazil
    • 7.5.5.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.5.5.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.5.5.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.5.5.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.5.5.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.5.6. Mexico
    • 7.5.6.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.5.6.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.5.6.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.5.6.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.5.6.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.5.7. Argentina
    • 7.5.7.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.5.7.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.5.7.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.5.7.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.5.7.3. Market estimates and forecast, by end-use, 2013 - 2024
  • 7.6. Middle East & Africa
    • 7.6.1. Market estimates and forecast, by country, 2013 - 2024
    • 7.6.2. Market estimates and forecast, by technology, 2013 - 2024
    • 7.6.2.1. Market estimates and forecast, by screening, 2013 - 2024
    • 7.6.2.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.6.3. Market estimates and forecast, by disease, 2013 - 2024
    • 7.6.4. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.6.5. Saudi Arabia
    • 7.6.5.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.6.5.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.6.5.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.6.5.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.6.5.3. Market estimates and forecast, by end-use, 2013 - 2024
    • 7.6.6. South Africa
    • 7.6.6.1. Market estimates and forecast, by technology, 2013 - 2024
        • 7.6.6.1.1. Market estimates and forecast, by screening, 2013 - 2024
        • 7.6.6.1.2. Market estimates and forecast, by diagnostic, 2013 - 2024
    • 7.6.6.2. Market estimates and forecast, by disease, 2013 - 2024
    • 7.6.6.3. Market estimates and forecast, by end-use, 2013 - 2024

Chapter 8. Company Profiles

  • 8.1. Abbott
    • 8.1.1. Business overview
    • 8.1.2. Financial data
    • 8.1.3. Product landscape
    • 8.1.4. Strategic outlook
    • 8.1.5. SWOT analysis
  • 8.2. Agilent
    • 8.2.1. Business overview
    • 8.2.2. Financial data
    • 8.2.3. Product landscape
    • 8.2.4. Strategic outlook
    • 8.2.5. SWOT analysis
  • 8.3. AutoGenomics
    • 8.3.1. Business overview
    • 8.3.2. Financial data
    • 8.3.3. Product landscape
    • 8.3.4. Strategic outlook
    • 8.3.5. SWOT analysis
  • 8.4. Ariosa Diagnostics
    • 8.4.1. Business overview
    • 8.4.2. Financial data
    • 8.4.3. Product landscape
    • 8.4.4. Strategic outlook
    • 8.4.5. SWOT analysis
  • 8.5. Baebies
    • 8.5.1. Business overview
    • 8.5.2. Financial data
    • 8.5.3. Product landscape
    • 8.5.4. Strategic outlook
    • 8.5.5. SWOT analysis
  • 8.6. Berry Genomics Co. Ltd
    • 8.6.1. Business overview
    • 8.6.2. Financial data
    • 8.6.3. Product landscape
    • 8.6.4. Strategic outlook
    • 8.6.5. SWOT analysis
  • 8.7. BGI
    • 8.7.1. Business overview
    • 8.7.2. Financial data
    • 8.7.3. Product landscape
    • 8.7.4. Strategic outlook
    • 8.7.5. SWOT analysis
  • 8.8. Biocartis Group NV
    • 8.8.1. Business overview
    • 8.8.2. Financial data
    • 8.8.3. Product landscape
    • 8.8.4. Strategic outlook
    • 8.8.5. SWOT analysis
  • 8.9. Bio-Rad Laboratories, Inc.
    • 8.9.1. Business overview
    • 8.9.2. Financial data
    • 8.9.3. Product landscape
    • 8.9.4. Strategic outlook
    • 8.9.5. SWOT analysis
  • 8.10. Illumina Inc.
    • 8.10.1. Business overview
    • 8.10.2. Financial data
    • 8.10.3. Product landscape
    • 8.10.4. Strategic outlook
    • 8.10.5. SWOT analysis
  • 8.11. Laboratory Corporation of America
    • 8.11.1. Business overview
    • 8.11.2. Financial data
    • 8.11.3. Product landscape
    • 8.11.4. Strategic outlook
    • 8.11.5. SWOT analysis
  • 8.12. Masimo Corporation
    • 8.12.1. Business overview
    • 8.12.2. Financial data
    • 8.12.3. Product landscape
    • 8.12.4. Strategic outlook
    • 8.12.5. SWOT analysis
  • 8.13. Natera Inc.
    • 8.13.1. Business overview
    • 8.13.2. Financial data
    • 8.13.3. Product landscape
    • 8.13.4. Strategic outlook
    • 8.13.5. SWOT analysis
  • 8.14. Perkinelmer, Inc.
    • 8.14.1. Business overview
    • 8.14.2. Financial data
    • 8.14.3. Product landscape
    • 8.14.4. Strategic outlook
    • 8.14.5. SWOT analysis
  • 8.15. Progenity, Inc.
    • 8.15.1. Business overview
    • 8.15.2. Financial data
    • 8.15.3. Product landscape
    • 8.15.4. Strategic outlook
    • 8.15.5. SWOT analysis
  • 8.16. Qiagen
    • 8.16.1. Business overview
    • 8.16.2. Financial data
    • 8.16.3. Product landscape
    • 8.16.4. Strategic outlook
    • 8.16.5. SWOT analysis
  • 8.17. Sequenom Inc.
    • 8.17.1. Business overview
    • 8.17.2. Financial data
    • 8.17.3. Product landscape
    • 8.17.4. Strategic outlook
    • 8.17.5. SWOT analysis
  • 8.18. Trivitron Healthcare Private Limited
    • 8.18.1. Business overview
    • 8.18.2. Financial data
    • 8.18.3. Product landscape
    • 8.18.4. Strategic outlook
    • 8.18.5. SWOT analysis

Data Tables

  • TABLE 1. Prenatal and newborn genetic testing industry 360 degree synopsis, 2013 - 2024
  • TABLE 2. Global prenatal and newborn genetic testing market, 2013 - 2017 (USD Million)
  • TABLE 3. Global prenatal and newborn genetic testing market, 2018 - 2024 (USD Million)
  • TABLE 4. Global prenatal and newborn genetic testing market, by technology, 2013 - 2017 (USD Million)
  • TABLE 5. Global prenatal and newborn genetic testing market, by technology, 2018 - 2024 (USD Million)
  • TABLE 6. Global prenatal and newborn genetic testing market, by disease, 2013 - 2017 (USD Million)
  • TABLE 7. Global prenatal and newborn genetic testing market, by disease, 2018 - 2024 (USD Million)
  • TABLE 8. Global prenatal and newborn genetic testing market, by end-use, 2013 - 2017 (USD Million)
  • TABLE 9. Global prenatal and newborn genetic testing market, by end-use, 2018 - 2024 (USD Million)
  • TABLE 10. Global prenatal and newborn genetic testing market, by region, 2013 - 2017 (USD Million)
  • TABLE 11. Global prenatal and newborn genetic testing market, by region, 2018 - 2024 (USD Million)
  • TABLE 12. Industry impact forces
  • TABLE 13. Screening market size, by region, 2013 - 2024 (USD Million)
  • TABLE 14. Non-invasive prenatal testing market size, by region, 2013 - 2024 (USD Million)
  • TABLE 15. Chorionic Villus Sampling market size, by region, 2013 - 2024 (USD Million)
  • TABLE 16. Amniocentesis market size, by region, 2013 - 2024 (USD Million)
  • TABLE 17. Maternal Serum Screening market size, by region, 2013 - 2024 (USD Million)
  • TABLE 18. Diagnostic market size, by region, 2013 - 2016 (USD Million)
  • TABLE 19. mmPCR market size, by region, 2013 - 2024 (USD Million)
  • TABLE 20. Spectrophotometer market size, by region, 2013 - 2024 (USD Million)
  • TABLE 21. FISH market size, by region, 2013 - 2024 (USD Million)
  • TABLE 22. ASSAYS market size, by region, 2013 - 2024 (USD Million)
  • TABLE 23. Down's syndrome market size, by region, 2013 - 2024 (USD Million)
  • TABLE 24. Phenylketonuria market size, by region, 2013 - 2024 (USD Million)
  • TABLE 25. Cystic fibrosis market size, by region, 2013 - 2024 (USD Million)
  • TABLE 26. Sickle cell anemia market size, by region, 2013 - 2024 (USD Million)
  • TABLE 27. Others market size, by region, 2013 - 2024 (USD Million)
  • TABLE 28. Hospitals market size, by region, 2013 - 2024 (USD Million)
  • TABLE 29. Maternity & Specialty Clinics market size, by region, 2013 - 2024 (USD Million)
  • TABLE 30. Diagnostic Centers market size, by region, 2013 - 2024 (USD Million)
  • TABLE 31. North America prenatal and newborn genetic testing market size, by country, 2013 - 2024 (USD Million)
  • TABLE 32. North America prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 33. North America prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 34. North America prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 35. North America prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 36. North America prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 37. U.S. prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 38. U.S. prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 39. U.S. prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 40. U.S. prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 41. U.S. prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 42. Canada prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 43. Canada prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 44. Canada prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 45. Canada prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 46. Canada prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 47. Europe prenatal and newborn genetic testing market size, by country, 2013 - 2024 (USD Million)
  • TABLE 48. Europe prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 49. Europe prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 50. Europe prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 51. Europe prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 52. Europe prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 53. Germany prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 54. Germany prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 55. Germany prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 56. Germany prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 57. Germany prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 58. UK prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 59. UK prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 60. UK prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 61. UK prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 62. UK prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 63. Italy prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 64. Italy prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 65. Italy prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 66. Italy prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 67. Italy prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 68. France prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 69. France prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 70. France prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 71. France prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 72. France prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 73. Spain prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 74. Spain prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 75. Spain prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 76. Spain prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 77. Spain prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 78. Rest of Europe prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 79. Rest of Europe prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 80. Rest of Europe prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 81. Rest of Europe prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 82. Rest of Europe prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 83. Asia Pacific prenatal and newborn genetic testing market size, by country, 2013 - 2024 (USD Million)
  • TABLE 84. Asia Pacific prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 85. Asia Pacific prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 86. Asia Pacific prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 87. Asia Pacific prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 88. Asia Pacific prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 89. China prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 90. China prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 91. China prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 92. China prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 93. China prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 94. India prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 95. India prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 96. India prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 97. India prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 98. India prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 99. Japan prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 100. Japan prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 101. Japan prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 102. Japan prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 103. Japan prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 104. Australia prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 105. Australia prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 106. Australia prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 107. Australia prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 108. Australia prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 109. Rest of Asia Pacific prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 110. Rest of Asia Pacific prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 111. Rest of Asia Pacific prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 112. Rest of Asia Pacific prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 113. Rest of Asia Pacific prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 114. Latin America prenatal and newborn genetic testing market size, by country, 2013 - 2024 (USD Million)
  • TABLE 115. Latin America prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 116. Latin America prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 117. Latin America prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 118. Latin America prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 119. Latin America prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 120. Brazil prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 121. Brazil prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 122. Brazil prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 123. Brazil prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 124. Brazil prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 125. Mexico prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 126. Mexico prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 127. Mexico prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 128. Mexico prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 129. Mexico prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 130. Argentina prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 131. Argentina prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 132. Argentina prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 133. Argentina prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 134. Argentina prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 135. Rest of Latin America prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 136. Rest of Latin America prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 137. Rest of Latin America prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 138. Rest of Latin America prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 139. Rest of Latin America prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 140. MEA prenatal and newborn genetic testing market size, by country, 2013 - 2024 (USD Million)
  • TABLE 141. MEA prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 142. MEA prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 143. MEA prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 144. MEA prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 145. MEA prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 146. South Africa prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 147. South Africa prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 148. South Africa prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 149. South Africa prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 150. South Africa prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 151. Saudi Arabia prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 152. Saudi Arabia prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 153. Saudi Arabia prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 154. Saudi Arabia prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 155. Saudi Arabia prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)
  • TABLE 156. Rest of MEA prenatal and newborn genetic testing market size, by technology, 2013 - 2024 (USD Million)
  • TABLE 157. Rest of MEA prenatal and newborn genetic testing market size, by screening, 2013 - 2024 (USD Million)
  • TABLE 158. Rest of MEA prenatal and newborn genetic testing market size, by diagnostic, 2013 - 2024 (USD Million)
  • TABLE 159. Rest of MEA prenatal and newborn genetic testing market size, by disease, 2013 - 2024 (USD Million)
  • TABLE 160. Rest of MEA prenatal and newborn genetic testing market size, by end-use, 2013 - 2024 (USD Million)

Charts & Figures

  • FIG. 1 Industry segmentation
  • FIG. 2 Global prenatal and new-born genetic testing market, 2013 - 2024 (USD Million)
  • FIG. 3 Growth potential analysis, by technology
  • FIG. 4 Growth potential analysis, by disease
  • FIG. 5 Growth potential analysis, by end-use
  • FIG. 6 Porter's analysis
  • FIG. 7 Strategy dashboard
  • FIG. 8 PESTEL analysis
Back to Top